Concise Reviews: Targeting Cancer Stem Cells Using Immunologic Approaches

QIN PAN, a,b QIAO LI, a SHUANG LIU, c NING NING, a,d XIAOLIAN ZHANG, b YINGXIN XU, d ALFRED E. CHANG, a MAX S. WICHA a

Key Words. Cancer stem cells • Immunotherapy • Lymphocytes • Cytotoxic T lymphocytes

ABSTRACT

Cancer stem cells (CSCs) represent a small subset of tumor cells which have the ability to self-renew and generate the diverse cell types that comprise the tumor bulk. They are responsible for local tumor recurrence and distant metastasis. However, they are resistant to conventional radiotherapy and chemotherapy. Novel immunotherapeutic strategies that specifically target CSCs may improve the efficacy of cancer therapy. To immunologically target CSC phenotypes, innate immune responses to CSCs have been reported using Natural killer cells and γδ T cells. To target CSC specifically, in vitro CSC-primed T cells have been successfully generated and shown targeting of CSCs in vivo after adoptive transfer. Recently, CSC-based dendritic cell vaccine has demonstrated significant induction of anti-CSC immunity both in vivo in immunocompetent hosts and in vitro as evident by CSC reactivity of CSC vaccine-primed antibodies and T cells. In addition, identification of specific antigens or genetic alterations in CSCs may provide more specific targets for immunotherapy. ALDH, CD44, CD133, and HER2 have served as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. Finally, since CSCs are regulated by interactions with the CSC niche, these interactions may serve as additional targets for CSC immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell, for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well as the immune checkpoint (PD1/PDL1, etc.) may provide additional novel strategies to enhance the immunological targeting of CSCs. STEM CELLS 2015; 00:000—000

INTRODUCTION

Cancer stem cells (CSCs) are defined as malignant cancer cells that retain the ability to self-renew and differentiate generating nonmalignant cancer cells that form a tumor mass [1]. CSCs are believed to play important roles in tumor initiation, relapse, metastasis, and resistance to treatment [2]. These properties highlight the importance of developing therapeutic strategies to target the CSC population. Major conceptual and technical advances in immunology over the past 25 years have led to a new understanding of cellular and molecular interactions between the immune system and tumor cells. In parallel, recent advances in tumor immunotherapy have provided powerful new therapeutic approaches that have produced durable clinical responses with limited toxicities in a small subset of patients [3]. Although it is currently not known what accounts for these durable remissions receiving immunotherapy, the possibility that this may be related to the ability of these therapies to target CSCs warrants further exploration. If this is demonstrated, then immunologic strategies specifically designed to target CSCs may increase the proportion of patients experiencing these durable remissions. Since CSCs drive tumor progression and metastasis, long-term benefit of cancer therapies involving conventional approaches such as surgery, chemotherapy, and/or radiation therapy may depend on their ability to effectively target CSCs.

CSCs are Resistant to Conventional Therapeutic Agents

Despite advances in radiation therapy and chemotherapy, the prognosis of patients with advanced malignant tumors remains poor. Ineffective targeting of CSCs has been suggested as one reason for current treatment failure [4]. CSCs have been documented to be resistant to various chemotherapeutic agents and radiotherapy [5–7]. The resistance of CSCs to chemotherapy may involve increased expression of drug efflux pumps, more efficient DNA repair [5, 8], and interactions of CSCs with their microenvironment [9, 10]. In light of CSC resistance to conventional therapeutic agents,
targeting of cancer stem cells represents a significant factor contributing to current treatment failure. Abbreviation: CSC, cancer stem cell.

development of alternative/novel therapeutic strategies that can specifically and effectively target CSCs is needed to enhance the efficacy of other therapeutic agents (Fig. 1).

**IMMUNOLOGICAL TARGETING OF CSC PHENOTYPES**

There are a number of theoretical reasons which provide a rationale for developing immune approaches to target CSCs. It is clear that CSCs and their more differentiated progeny display distinct gene expression profiles and therefore express different antigens. Immunologic approaches directed against whole tumors are largely biased toward more differentiated tumor cells which form the bulk of the tumor and which express “differentiation” antigens. This suggests that effective immune targeting of CSC may require the specific targeting of this cell population. In addition, within a tumor, CSCs may themselves exhibit heterogeneity resulting from both genetic and epigenetic regulation associated with tumor progression and metastasis. For instance, we [11] have shown that breast CSCs maintain that plasticity to transition between mesenchymal (EMT) and epithelia (MET) states in a process regulated by the tumor microenvironment. The ability of immunotherapies to target multiple antigens makes these approaches well suited to the targeting of these heterogenous CSC populations.

**Innate Immune Response to CSCs**

Natural killer (NK) cells are major effector cells for innate immunity, making them suitable candidates for immunotherapy of both hematologic and solid tumors [12, 13]. However, the role of NK cells in anti-CSC immune surveillance remains controversial. Wu et al. investigated the immunogenicity of CD133+ brain tumor stem cells (BTSCs). Their data revealed that the majority of CD133+ cells do not express detectable MHC I or NK cell activating ligands, which may render them resistant to adaptive and innate immune surveillance [14]. Wang et al. also reported that MICA and MICB (MHC class I-related chain A and B), two ligands for the stimulatory NK cell receptor NKG2D, are downregulated due to aberrant expression of oncogenic miR-20a in human breast CSCs, which resulted in immune escape of these CSCs from NK cell killing [15]. In contrast, Castriconi et al. reported that glioma stem cells (GSCs) express various ligands of NK cell activation receptors that trigger optimal NK cell cytotoxicity. They found that GSCs are highly susceptible to lysis mediated by both allogeneic and autologous IL-2 (or IL-15)-activated NK cells [16]. Tseng et al. also showed that primary oral squamous (OS) carcinoma stem cells are significantly more susceptible to NK cell-mediated cytotoxicity than their differentiated counterparts [17]. Tallerico et al. analyzed the NK cell recognition of colorectal adenocarcinoma CSCs. They demonstrated that allogeneic NK cells can recognize and kill these CSCs but the non-CSC counterpart is less susceptible to NK cells. Compared with the non-CSCs, these colorectal CSCs express higher levels of ligands for the natural cytotoxicity receptors which mediates NK cell killing and lower levels of MHC class I [18].

Unconventional γδ T cells represent another group of innate immune effector cells, which constitute 1%–5% of circulating lymphocytes and are of the Vγ9Vδ2 phenotype. Immunotherapy with γδ T cells is of substantial interest based on their potent non-HLA-restricted cytotoxicity against different tumor entities and their capacity to recognize and present antigens to αβ T cells [19, 20]. γδ T cells primarily target isopentenyl pyrophosphate, an intermediate of the mevalonate pathway for isoprenoid biosynthesis in eukaryotic cells [21, 22]. Nishio et al. showed that Vγ9Vδ2 T cells mediate cytolysis of sphere-forming neuroblastoma cells sensitized with zolendronate [23]. Todaro et al. also reported that Vγ9Vδ2 T cells are induced to proliferate, secrete TNF-α and IFN-γ, and produce the cytotoxic and apoptotic molecules TRAIL and granzymes after exposure to zolendronate-sensitized human colon CSCs [24]. In a clinical study, activated Vγ9Vδ2 T cells in combination with zolendronate show increased CD69 expression, indicating an activated phenotype. These Vγ9Vδ2 T cells displayed upregulated expression of peripheral tissue-homing chemokine receptors, CCR5 and CXCR3. In contrast, there was a decrease in expression of the lymphoid-homing receptors, CCR7 and CXCR5 [23]. These Vγ9Vδ2 T cells were cytotoxic in vitro, and adoptively transferred Vγ9Vδ2 T cells trafficked predominantly to the lung, liver, and spleen as well as to the metastatic tumor sites outside these organs [25]. These results indicate that in vitro expansion of autologous γδ T cells in combination with other antitumor agents may benefit cancer treatment via CSC destruction. Further studies are needed to confirm direct targeting of CSCs by γδ T cells. There is a paucity of clinical studies involving the use of nonspecific killer cells in the adoptive immunotherapy of solid tumors that have examined effects on CSCs.

**In Vitro CSC-Primed T Cells Specifically Target CSCs In Vivo**

CD8+ T cells undergo proliferation and differentiate into cytotoxic T lymphocytes (CTLs) in the presence of appropriate stimulation [26]. Activated CTLs can migrate to peripheral tissues where they exert two major effector functions: direct contact-mediated cytotoxicity and secretion of effector cytokines, such as IFN-γ and TNF-α. Another essential function of activated CD8+ T cells is the acquisition of memory. Memory CD8+ T cells can be maintained for long periods of time without antigenic stimulation and potentiate a more potent and faster immune response of the host upon cancer relapse or development of metastasis [27]. CD4+ T helper cells also play a critical role in the development of effective antitumor immunity by increasing clonal expansion of CTL at the tumor
CSC-specific CD8$^+$ T cells were generated from human acute myeloid leukemia (AML) stem cells in 1999 by Bonnet et al., and were observed to mediate tumor regression after injection into NOD/SCID mice [29]. Brown et al. isolated CD133$^+$ BTSCs, and demonstrated that these BTSCs are susceptible to perforin-dependent CTL-mediated cytolysis [30]. To assess whether the protein processing machinery is sufficiently intact for the BTSCs population to process and present antigen for CD8$^+$ CTL recognition, the authors engineered glioma tumor sphere (TSs) to endogenously express the cytomegalovirus (CMV) pp65 antigen by reconstructed pp65-lentiviral transduction. They found that CMV-specific CTLs mediate the CMV-transduced glioma TSs cytopoxygen. When CMV pp65-expressing TSs and pp65-specific CTLs were coinfected into NOD/SCID mice, the pp65 antigen-positive tumor cells were ablated, whereas pp65$^{-}$ tumor cells were resistant to the pp65-specific CTL and efficiently engrafted. This result indicated that direct recognition of antigen by CTLs is required to eliminate tumor initiation [30].

In another study, Visus and colleagues generated CSC-specific CD8$^+$ T cells using antigenic peptide from ALDH1A1. The transfer of ALDH1A1-specific CD8$^+$ T cells eliminated ALDH1A$^{+}$bright CSCs from squamous cell carcinoma of the head and neck, inhibited tumor growth and metastases, and prolonged survival of xenograft-bearing immunodeficient mice [31, 32]. Together, these studies suggest that CSC-specific T cells can be generated in vitro for subsequent adoptive transfer into tumor-bearing hosts to target CSCs and eradicate tumors in vivo. In addition, these studies have demonstrated that CSCs are sensitive to T-cell-mediated killing. One problem with targeting CSCs with CSC-specific T cells in an adoptive immunotherapy approach is the immune escape of tumors with antigen loss. In the next section, we describe a method of generating CSC-specific T- and B-cell responses in vivo using a vaccine approach and how to mitigate against antigen loss variants.

Interestingly, CSCs seem to be able to evolve strategies to escape T-cell attack. Recently Volonté et al. reported that CSCs derived from colorectal cancer show weak immunogenicity compared with non-CSC counterparts. This feature may correlate with the expression of high levels of IL-4 by the CSCs because neutralization of CSC-associated IL-4 can rescue the proliferative activity of T lymphocytes [33]. Based on the results in this study, new immunotherapy protocols to target CSCs might involve blocking inhibitory activity of immunomodulatory molecules as well as activating T cell by CSC specific or associated antigens.

CSC-Based Vaccines Target CSCs in Immunocompetent Hosts

The use of professional antigen presenting cells, such as dendritic cells (DCs), to initiate tumor-specific T-cell responses represents a promising strategy for cancer vaccination approaches. Glioblastoma-derived CSCs express MHC I [34]. After coculturing human immature, autologous DCs with irradiated BTSCs, the CSC-primed mature DCs expressed costimulatory molecules CD80, CD86, and CD40, and stimulated significant Th1 (IFN-γ) response in vitro [34]. These studies demonstrate that CSCs may be antigenic and can be used to develop cell-specific vaccines. The efficacy of a tumor-specific vaccine in vivo is dependent upon both cellular and humoral host immunity. However, to date most CSC studies have been performed with human tumor-derived CSCs in NOD/SCID mice [29]. Due to the lack of cellular and humoral immunity, these immunocompromised mice are not suitable for assessing the efficacy of CSC vaccines. The lack of an intact host immune system prevents evaluation of multiple interactions that occur such as epitope spreading, antigen cross-presentation, and immune evasion mechanisms such as T regulatory cells or myeloid-derived suppressor cells; to name a few.

Based on this consideration, our group assessed the effects of CSC-DC vaccine in various syngeneic immunocompetent mouse tumor models, and demonstrated that CSC-DC vaccination significantly prevents lung metastasis of melanoma cells and inhibits tumor growth of squamous carcinoma compared to immunization with bulk tumor cells [35]. In this study, the tumorigenicity of murine aldehyde dehydrogenase (ALDH)$^{+}$/high CSCs were demonstrated in two histologically different tumor (DS melanoma and SCC7 squamous cell carcinoma) from two genetically distinct immunocompetent hosts (B6 and C3H mice) [35]. We used CSCs selected by virtue of their expression of the CSC marker, ALDH as an antigen source to prime DCs, and evaluated the protective effects of CSC-primed DC vaccines in mouse tumor challenge models [35]. This study demonstrated that CSC-primed DC vaccination was significantly more effective at preventing lung metastasis in the D5 model and subcutaneous tumor growth in the SCC7 model compared with control mice given DCs pulsed with unsorted heterogeneous tumor cells or ALDH$^{-}$/low non-CSCs. Systemic anti-CSC immunity was associated with CSC-specific IgG and CSC-specific CTLs present in the peripheral blood of CSC-DC vaccinated hosts. These data indicate that enriched CSCs are immunogenic and more effective as an antigen source than unselected tumor cells or non-CSCs in inducing antitumor immunity against CSC epitopes [35]. Consistent with these observations, Phuc et al. reported that breast CSC-DC vaccine could migrate to the spleen, activate CD8$^+$ and CD4$^+$ T cells, and induce CTL antitumor responses [36]. Currently, we hypothesize that CSCs may have multiple epitopes that are distinct from non-CSCs and which can be targeted by T or B cells. Work is currently underway to identify these antigens. The use of tumor lysates of CSCs as a source of antigen would potentially allow targeting multiple antigens simultaneously; and would be less susceptible to antigen loss as a means of tumor escape.

A number of studies have suggested that tumor vaccines have their greatest efficacy in the setting of micrometastatic disease. Due to the low percentage of CSCs within established tumor masses, CSC-targeted DC vaccines may have minimal effect on tumor size. We postulate that CSC-DC may have maximum utility when deployed in an adjuvant setting after surgical removal of the bulk tumor mass to target microscopic residual CSCs or as combinatorial therapy with radiation and/or chemotherapy in the therapy of established macroscopic tumors. Using an established murine tumor model, we found that treatment of microscopic tumor by CSC-DC was more efficacious that DCs pulsed with non-CSCs (Lin et al., in press, Oncoimmunology, 2015). Furthermore, in the established macroscopic tumor setting, the combination of radiation therapy (RT) plus CSC-DC vaccine was more effective than RT alone or CSC-DC
alone in reducing tumor growth and improving survival (Lin et al., in press, OncoImmunology, 2015). In assessing the percentage of CSC in the treated primary tumors, RT alone resulted in an increased percent of CSC whereas CSC-DC resulted in significant decrease in the percent of CSC (Lin et al., in press, OncoImmunology, 2015). Mice treated with the combination of RT and CSC-DC vaccine had significantly fewer spontaneous lung metastases compared with other control groups indicating the relationship between the ability to target CSC and a reduction in spontaneous metastatic disease (Lin et al., in press, OncoImmunology, 2015).

**IMMUNOLOGICAL TARGETING OF CSC ANTIGENS**

Cancer immunotherapy is based on the ability of the immune system to recognize cancer cells and to affect their growth and expansion. This suggests that proteins express on CSCs may provide targets for CSC immunotherapies. CSCs express various markers, including ALDH, CD44, CD133, and HER2, at levels substantially different from the bulk tumor cell population. These markers have proven useful for identifying and isolating CSCs. These CSC markers may provide specific targets for CSC immunotherapies.

**ALDH**

ALDH is responsible for the oxidation of aldehydes to carboxylic acids to prevent cells from oxidative insult and facilitate their survival. Increased ALDH activity has been found in CSCs of various tumor types, such as bladder, breast, colon, gastric, head and neck, lung, pancreatic, prostate as well as hematopoietic and neural stem/progenitor cells [37–46]. In addition, ALDH-mediated detoxification of toxic aldehyde intermediates produced in cancer cells treated with certain chemotherapy agents has been proposed to confer drug-resistant properties to ALDHhigh tumor cells [45]. Dylla et al. found that using short hairpin RNA against ALDH1 sensitized human colorectal CSCs to cyclophosphamide [47]. Raha et al. defined a requirement for ALDH in the maintenance of a drug-tolerant subpopulation of cancer cells that share some properties with CSCs. ALDH protects these CSCs from the potentially toxic effects of elevated levels of reactive oxygen species in the cells [48].

Immunological targeting of ALDH activity in vitro and in vivo has been reported by several groups. Visus et al. generated ALDH-specific CD8+ T cells that recognized and eliminated the ALDHhigh tumor cells in human carcinomas [32]. In this work, ALDH-specific CD8+ T cells were induced expanded by in vitro stimulation of human CD8+ T cells with ALDH peptide-pulsed autologous DCs. The percentages of ALDHhigh cells were decreased by 60%–89% resulting from ALDH-specific CD8+ T-cell-mediated cytolysis in vitro. Preclinical models using human tumor xenografts in immunodeficient mice, ALDH-specific CD8+ T cells inhibited xenograft growth and metastases, and prolonged survival after adoptive transfer. These results clearly demonstrated that ALDH can serve as potential target for T-cell-based immunotherapy to eliminate CSCs [32].

In addition to ALDH being a CSC marker, there is increasing evidence that it plays an important functional role in these cells. For example, Wang et al. demonstrated that disulfiram (DSF) an irreversible inhibitor of ALDH activity blocked the formation of radiation-induced breast CSCs [49]. In their work, irradiation-induced stemness correlates with increased spontaneous lung metastasis in syngeneic mouse mammary tumor models. However, irradiation-induced stemness was blocked by targeting ALDH activity with DSF. Treatment of mice with radiation and DSF significantly inhibited mammary primary tumor growth and spontaneous lung metastasis, which was associated with decreased CSCs [49]. The demonstration of an important role of ALDH in CSC function provides an additional rationale for using it as a target for immunotherapy since it might reduce the likelihood of immune escape through downregulated expression.

**CD44**

Cell surface CD44, a highly glycosylated type-1 transmembrane p-glycoprotein (~90 kDa), is among the most widely used CSC markers [50]. CD44 is present in multiple species generated by alternative splicing. Differently spliced variants include the V6 isoform in colon cancer CSCs [50] and the standard isoform in breast CSCs [51]. CD44 is involved in multiple signaling functions, for example, cell proliferation, apoptosis, survival, migration, and differentiation [52]. Moreover, a recent study reveals that the CD44 protein plays an important role in a number of CSC functions including self-renewal, niche preparation, epithelial-mesenchymal transition, and resistance to apoptosis [53].

Considering that CD44 has its functional roles and is a marker on CSCs, targeting CD44 with immunological approaches represents a promising strategy to eliminate CSCs. In 1993, Seiter et al. first reported that monoclonal antibody 1.1ASML against a splice variant of CD44 (CD44v) retarded growth of lymph node and lung metastases from pancreatic adenocarcinoma in rats [54]. Since then, anti-CD44 antibodies have been shown to promote terminal differentiation of AML blasts [55], inhibit growth of murine mammary carcinoma cells and human colon carcinoma cells and induce apoptosis [56], and decrease human melanoma metastasis and increase animal survival in SCID mice [57]. Given these results, recently several anti-CD44 antibodies have been developed and used in anti-CSC approach [58–60]. Jin et al. used the anti-CD44 monoclonal antibody H90 to selectively eradicate AML CSCs in NOD/SCID mice [58, 59]. They found that H90 blocked leukemic stem cells trafficking to their supportive microenvironment and altered stem cell fate [58]. Young et al. also described that H460-16-2, a humanized anti-CD44 monoclonal antibody, is able to reduce the growth of BxPC3 pancreatic cancer xenografts by 80%. In addition, it has been demonstrated that in AML xenografts H460-16-2 binds to CD34+CD38− CSCs increasing mouse survival. Clinical trials using this antibody are planned [60].

**CD133**

Human CD133 (human prominin-1) is expressed on CSCs in a number of solid tumors [61, 62]. Recent studies have shown that the CD133+ subpopulation displays resistance to chemotherapy and radiotherapy, and high CD133 expression is a marker of poor prognosis [62]. Several monoclonal antibodies to CD133 have been generated [63, 64]. Our group recently generated an anti-CD3/anti-CD133 bispecific antibody (BsAb) and bound it to the cytokine-induced killer (CIK) cells as effector cells (BsAb-CIK) to target CD133high CSCs. We found that killing of CD133high pancreatic (SW1990) and hepatic (Hep3B) cancer cells by the BsAb-CIK cells was significantly higher than...
the killing by the parental CIK or by CIK cells bound with anti-CD3 (CD3-CK) without CD133 targeting. In nude mice, the BsAb-CIK cells inhibited CD133<sup>high</sup> tumor growth significantly more than that by CIK or CD3-CK cells, or BsAb alone. Mechanistically, treatment with the BsAb-CIK cells significantly downregulated the expression of S100P and IL-18bp, but upregulated STAT1. These findings suggest a novel immunotherapy for patients with cancer containing CD133<sup>high</sup> CSCs involving selective targeting of this cell population [65].

**HER2**

Human epidermal growth factor receptor-2 (HER2) is over-expressed in several human cancers of epithelial origin where it plays an essential role in tumor development [65–67]. It has been shown that over-expression of HER2 in breast cancer is often associated with an aggressive course characterized by increased disease recurrence and a poor prognosis. Specifically, we have shown that the level of ALDH in HER2<sup>−</sup> breast cancer is much higher than that in HER2<sup>+</sup> breast cancers. HER2 regulates the mammary stem/progenitor cell population, driving tumorigenesis, invasion, and HER2-associated radioresistance of breast CSCs [6, 67, 68]. We have shown that in HER2<sup>+</sup> breast cancers, HER2 regulates CSC self-renewal [68] and that this is mediated by a pathway involving Akt and β-Catenin [69] and have suggested that the ability of HER2 targeting agents to eliminate CSC may contribute to their remarkable clinical efficacy. In addition, to playing a role in HER2<sup>+</sup> breast cancers we recently showed [67, 70] that in luminal breast cancers that are considered HER2 negative, HER2 is selectively expressed in the ALDH<sup>high</sup> CSC population. Fluorescence-activated cell sorting analysis of ALDH<sup>high</sup> versus ALDH<sup>low</sup> cells showed enrichment for HER2 expression in ALDH<sup>high</sup> cells. In MCF7 and ZR75-1 human breast cancer luminal cell lines, the level of HER2 expression was considerably lower than in the HER2-amplified cell lines. However, in these cells, HER2 expression was increased two- to threefold in ALDH<sup>high</sup> cells (HER2<sup>+</sup>ALDH<sup>high</sup>) as compared to ALDH<sup>low</sup> cells (HER2<sup>−</sup>ALDH<sup>low</sup>). We have characterized the stem cell nature of the HER2<sup>+</sup>ALDH<sup>high</sup> cell [71]. We have proposed that HER2 expression in luminal CSCs in the absence of HER2 gene amplification may account for the surprising finding that the benefit of adjuvant trastuzumab may extend to patients whose tumors do not display HER2 gene amplification [71, 72].

In addition to the use of HER2 blocking antibodies, other immunologic approaches have been used to target HER2 expressing cells. Sen et al. reported that activated T cells armed with anti-CD3 × anti-HER2 bispecific antibody (HER2Bi) mediates high levels of specific cytotoxicity directed at both low and high HER2-expressing breast cancer cell lines [73]. Intravenous infusions of HER2Bi-armed T cells inhibited the growth of established HER2<sup>+</sup> PC-3 tumors in SCID/Beige mice and prevented tumor development in co-injection WINN assays [74, 75]. Arming T cells with HER2Bi converts every T cell into a non-MHC restricted HER2-specific CTL [73]. In a phase I clinical trial led by Lum et al. with infusion of anti-CD3 × anti-HER2 bispecific antibody armed T cells involving 23 HER2 negative (0–2<sup>−</sup> IHC) metastatic breast cancer patients, the median OS for the HER2 negative women was 25.9 months, considerably longer than expected from historic controls (personal communication with Dr. LG Lum). Apparently, HER2Bi armed T cells, while intended to target HER2, seem to benefit patients that are HER2-negative by classic criteria including lack of HER2 gene amplification as determined by fluorescence in situ hybridization. Our finding of selective HER2 expression in CSCs in these breast cancers classified as “HER2-negative” may provide a biological explanation for these clinical findings. However, the potential of infused HER2Bi armed T cells to specifically induce immune responses against breast CSCs remains untested.

**IMMUNOTHERAPEUTIC TARGETING OF THE CSC NICHE**

CSCs reside in a niche within the tumor, which contributes to the self-renewal and differentiation of these cells. Growth factors, cytokines, and diverse stromal cells, such as mesenchymal stem cells and immune cells in the cellular microenvironment, are essential for cell nutrition, intercellular communication, signal transduction, and cell fate [76]. For example, Lu et al. [77] recently demonstrated that tumor-associated monocytes and macrophages create a niche through juxtacrine signaling of CSCs. These studies suggest that components in CSC niche may provide additional therapeutic targets for eliminating CSCs.

**IMMUNE CELL/CYTOKINES (MYELOID–DERIVED SUPPRESSOR CELLS, IL–6, ETC.)**

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population including immature macrophages, DCs, granulocytes, and other myeloid cells at earlier stages of differentiation [78]. MDSCs can directly incorporate into tumor endothelium and secrete many proangiogenic factors. They also induce the production of matrix metalloproteinases, chemo attractants, and create a premetastatic environment [78]. Panni et al. demonstrated the role of MDSC in promoting the ALDH<sup>high</sup> CSCs in pancreatic cancer in a mouse model [79]. STAT3 signaling in MDSCs can be modulated by IL-6, which has been shown to enhance CSCs and EMT in cancer [80, 81]. Cui et al. also reported that MDSCs enhance CSC gene expression, sphere formation, and cancer metastasis in patients with ovarian carcinoma [82]. To the best of our knowledge, there are no published studies on targeting MDSCs for CSC elimination. However, given the roles of MDSCs in tumor invasion and metastasis, immunological targeting of MDSCs represents a rational approach for targeting CSCs.

Recently, Korkaya et al. demonstrated that monocytes and macrophages recruited to breast tumor directly regulate CSC through inflammatory cytokines IL-1, IL-6, and IL-8 in the CSC niche which are involved in driving CSC self-renewal [9]. These cytokines activate STAT3/NF-κB pathways in both tumor and stromal cells, which in turn stimulate further cytokine production, generating positive feedback loops that contribute to CSC self-renewal [10]. Inhibitors of these cytokines and their receptors have been developed and trials to use these inhibitors to block CSC self-renewal have been initiated [9, 83]. Immunologically, blockade of the IL-8 receptor CXCR1 using antibody or repertaxin (a small-molecule CXCR1 inhibitor) selectively depletes the CSC population in human breast cancer cell lines in vitro, followed by the induction of massive apoptosis in the bulk tumor population via FASL/FAS signaling [84]. In addition, IL-6 has been shown to be a direct regulator
for CSC self-renewal [85–87]. Anti-IL-6 antibody inhibited JAK1 and STAT3 activation as well as OCT-4 gene expression, thus inhibiting CSCs [88]. These studies suggest that IL-6R blockade may provide attractive therapies in attempt to immunologically target CSCs.

**Immune Checkpoints (PD-1/PD-L1)**

Immune checkpoints are cell surface molecules that serve as endogenous regulators of the immune response, limiting autoimmunity by mediating coinhibitory signaling pathways [89]. In cancer, these inhibitory pathways are involved in tumor immune-resistance [90]. To date, two major immunoinhibitory pathways have been recognized, namely the programmed cell death-1 (PD-1)/PD-L1 axis, and the CTL antigen 4 (CTLA-4)/B7 axis. These negative immune regulatory pathways have been proposed to contribute to a suppressive microenvironment that protects cancer cells from immune destruction [91, 92]. CSCs might reciprocally modulate the immune cells in CSC niche through the secretion of paracrine factors or direct cell-cell contact, based on the concept that physiologic stem cells have immunoprivilege and active immunoregulatory functions [93–97]. Schatton et al. reported evidence that CSCs downregulate T-cell activation [98, 99]. They identified a novel type of CSCs, malignant melanoma-initiating cells (MMIC), based on their expression of the chemoresistance determinant ABCBS [98]. Tumorigenic human ABCBS+ MMICs preferentially express PD-1 and B7.2, while having downregulated expression of PD-L1 compared to ABCBS- cells. Recently PD-1 and PD-L1 antibodies have been shown to have clinical benefit in a variety of cancers including melanoma and lung cancer [100, 101] and most recently in refractory Hodgkins disease [102]. In these studies, a subset of patients enjoy prolonged responses often considerably more durable that those produced by cytotoxic or even targeted therapies. It is postulated that expression of PD-L1 on tumors may downregulate activated T-cell responses via the PD-L1/PD-1 axis; and its block-

ade results in effective T-cell responses. Although Schatton et al. reported decreased PD-L1 expression on MMICs [99]; a recent study demonstrated preferential expression of PD-L1 on CSC in head and neck carcinoma [103]. This opens the possibility that subsets of CSCs may downregulate T-cell immunity via the PD-1/PD-L1 axis. Assessment of CSCs in future clinical trials involving immune checkpoint blockade will be necessary to determine whether this is the case. Furthermore, combination of immune checkpoint therapies with CSC targeting immunotherapies such as vaccines may enhance the clinical utility of each approach.

**SUMMARY**

Multiple immunotherapeutic approaches to target CSCs are in development. As outlined in Figure 2, these include direct targeting of CSCs with immunological methods, for example, CSC-DC vaccine; blocking the “help” to CSCs from the tumor microenvironment, for example, anti-IL-6 mAb, and inhibiting CSC-mediated immune suppression, for example, blockade with anti-PD-1/PD-L1 mAbs. It will be necessary to rigorously test these strategies alone or in combination to determine their therapeutic efficacy. However, immunologic targeting of CSCs represents a promising new direction in cancer therapeutics which we postulate will be more effective as combinatorial therapy with conventional modalities as well as with immunomodulatory agents.

**ACKNOWLEDGMENTS**

This work was supported by NIH Grant 1R56DE024385-01, The University of Michigan Round 10 MICH/CTSA Pilot Grant Programs T1-Bench to bedside collaborations award, and was partially supported by the Gillson Longenbaugh Foundation.

**AUTHOR CONTRIBUTIONS**

Q.P.: manuscript writing, collection and/or assembly of data, and data analysis and interpretation; Q.L. and A.E.C.: conception and design, financial support, manuscript writing, data analysis and interpretation, and final approval of manuscript; S.L., N.N., X.Z., and Y.X.: collection and/or assembly of data; M.S.W.: conception and design, financial support, administrative support, manuscript writing, data analysis and interpretation, and final approval of manuscript.

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

Max S. Wicha has consultant/advisory role with MedImmune, Verastem, and Paganini; research funding/contracted research with MedImmune and Dompe; and ownership interest with OncoMed.

**REFERENCES**


46 Balber AE. Concise review: Aldehyde dehydrogenase bright stem and progenitor cell populations from normal tissues: Characteristics, activities, and emerging uses in regenerative medicine. Stem Cells 2011;29:570–575.
60 Young D. Patent WO2007098571, 2007; Arius Research Inc.